Supplementary Materials

Supplementary Material for:

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

Peter Kiessling, Rocio Lledo-Garcia,* Shikiko Watanabe, Grant Langdon, Diep Tran, Muhammad Bari, Louis Christodoulou, Emma Jones, Graham Price, Bryan Smith, Frank Brennan, Ian White, Stephen Jolles

*Corresponding author. Email: rocio.lledo-garcia{at}ucb.com

Published 1 November 2017, Sci. Transl. Med. 9, eaan1208 (2017)
DOI: 10.1126/scitranslmed.aan1208

This PDF file includes:

  • Fig. S1. The effect of SC or IV dosing of rozanolixizumab (50 and 150 mg/kg every 3 days for 28 days) on mean plasma IgG concentrations in cynomolgus monkeys.
  • Fig. S2. Changes in selected plasma cytokine concentrations after single-dose rozanolixizumab in healthy subjects.

[Download PDF]